About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Alkem Laboratories Ltd.
Change Company
BSE Code
539523
ISIN Demat
INE540L01014
Book Value
1030.56
NSE Code
ALKEM
Dividend Yield %
0.92
Market Cap
584051.11
P/E
27.95
EPS
174.78
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
18-Jun-2025
Alkem Laboratories informs about change in direct...
11-Jun-2025
Alkem Laboratories informs about analyst meet
20-Mar-2025
Alkem Laboratories informs about analyst meet
18-Mar-2025
Alkem Laboratories informs about analyst meet
17-Mar-2025
Alkem Laboratories’ arm to acquire 100% stake in ...
17-Mar-2025
Alkem Laboratories gains as its arm to acquire 10...
13-Mar-2025
USFDA concludes BIMO inspection at Alkem Laborato...
12-Mar-2025
Alkem Laboratories launches 'Empanorm' medicine i...
12-Mar-2025
Alkem Laboratories informs about press release
10-Mar-2025
Alkem Laboratories informs about analyst meet
01-Mar-2025
Alkem Laboratories informs about disclosure
11-Feb-2025
Alkem Laboratories informs about transcript of co...
07-Feb-2025
Alkem Laboratories reports 6% rise in Q3 consolid...
05-Feb-2025
Alkem Laboratories gains on launching Kojiglo ser...
04-Feb-2025
Alkem Laboratories launches Kojiglo serum in India
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.